Scientific publications

Time for radioimmunotherapy: an overview to bring improvements in clinical practice

Aug 1, 2019 | Magazine: Clinical and Translational Oncology

O Leaman Alcibar, D Candini, F López-Campos, M Albert Antequera, V Morillo Macías, A J Conde, A Rodríguez Pérez, A Hervás Morón, J Contreras Martínez, C Ferrer Albiach, S Navarro Aguilar, M E Rodríguez-Ruiz


Harnessing the patient's own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical "checkpoints" that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient's own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity.

Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.

CITATION  Clin Transl Oncol. 2019 Aug;21(8):992-1004. doi: 10.1007/s12094-018-02027-1. Epub 2019 Jan 14.